Left: Detailed 3D reconstruction of the prostate showing different regions and seminal vesicles on the top. Localization of prostate cancer lesion in posterior peripheral zone automatically by QUIBIM’s AI algorithm for prostate cancer detection.
Right: Segmentation masks extracted automatically by QUIBIM’s AI technology after the application of a multi-class CNN (transitional zone, peripheral zone, seminal vesicles) on T2 images trained with a database of more than 9000 samples.

Men die about five years earlier than women across the world. As initiatives to boost awareness of men’s health unfolded in November, an international project is bringing the forefront of AI research to tackle prostate cancer (PC), the second most frequent type of cancer in men and the third most lethal in Europe.

Report: Mélisande Rouger

Over the next four years, the ProCAncer-I consortium will receive €10M EU funding to develop advanced AI models to meet clinical needs in diagnosis, metastases detection and prediction of response to treatment, by creating the world’s largest PC MRI database and validating solid algorithms.

ProstateNet: over 1.5M images to display prostate cancer

15 institutions across the EU, Turkey and the UK will work to gather over 1.5 million prostate cancer images taken in 17,000 multi-parametric MRI examinations into a unique collection called ProstateNet. Building a strong dataset is a must to unleash the power of deep learning in clinical practice, according to Nickolas Papanikolaou, Principal Investigator in Oncologic Imaging at Antonio Champalimaud Foundation, in Lisbon, and Scientific Director of the consortium. ‘The highest dataset that is publicly available, so far, comprises a few hundreds of examinations. But, to provide meaningful outcomes, you need to provide thousands. The reason deep learning fails to provide clinical value now is that you need big datasets,’ he pointed out.

Nickolas Papanikolaou
Source: Champalimaud Foundation

The project will count with the participation of renowned radiologists such as Daniele Regge,  from the University of Torino, who serves as Clinical Director, and Emmanuele Neri from the University of Pisa, to name some. The consortium will also develop and maintain a centralised data repository, which will become available for third parties through controlled access. A special governance committee will be formed to examine applications and grant or refuse access.

The third goal is to develop AI models that can harness information contained in these huge amounts of data, to answer clinical unmet needs along eight defined clinical use cases tackling the whole disease continuum – from detection all the way to treatment-related prediction or toxicity. This holistic approach was probably the reason the project received EU support, according to Papanikolaou: ‘We believe we have exhausted all the important pitfalls and current limitations in clinical practice, and we will try to solve these pitfalls through technology use.’

Reducing overdiagnosis by improving detection of aggressive disease

Massive screening by means of specific biomarkers like PSA result in overdiagnosis and overtreatment. ‘Unlike breast cancer, where a screening program can really save lives, overdiagnosis of prostate cancer is the outcome of using PSA as a screening tool,’ he explained.

PC is one of the most prevalent types of cancer, but most of these prostate cancers that are diagnosed through a biopsy are indolent – either they are very slow or don’t grow, staying confined within the gland. This means the vast majority of patients can live with the disease for two or three decades. The older a man gets, the higher his probability of developing PC. However, only 3% of those patients who are diagnosed with PC have the aggressive, life-threatening type. Being able to differentiate between aggressive and non-aggressive disease is therefore key. It’s absolutely crucial to be able to identify these few patients who have the highly aggressive form of cancer, because these are the ones we can save in principle if we treat them early,’ Papanikolaou  pointed out.

MRI backed by AI can help detect, characterise and stratify those cancers into clinically significant or non-clinically significant. MRI is mandatory before prostate biopsy, because the modality helps improve prostate cancer detection and eases biopsy guidance. But’ Papanikolaou explained, ‘if there is only a radiologist to look at MRI images to evaluate PC, subjective variability remains a problem that AI can help to overcome. Radiologists don’t have the same diagnosis for the same patients and even disagree with themselves if you show them MRI images multiple times. Based on what radiologists say, a focused biopsy will be planned and the patient will be operated on. But radiologists now cannot significantly differentiate between non-significant disease and significant disease, and cannot really differentiate it biological-wise,’ Papanikolaou said.

Source: https://healthcare-in-europe.com/en/news/fighting-prostate-cancer-with-over-1-5-million-mri-images.html

Highlights

Ελπίδα από Έλληνες επιστήμονες για τον καρκίνο του προστάτη

Ελπίδα από Έλληνες επιστήμονες για τον καρκίνο του προστάτη

Ελπίδα για καλύτερη διάγνωση, θεραπεία και βελτιωμένη ποιότητα ζωής στους ασθενείς που πάσχουν από καρκίνο του προστάτη, δίνει το νέο πανευρωπαϊκό πρόγραμμα ProCAncer-I στο οποίο συμμετέχει και η Ελλάδα καθώς συντονιστής φορέας είναι το Ινστιτούτο Τεχνολογίας και Έρευνας (ΙΤΕ) στην Κρήτη.

Novartis prostate cancer drug receives U.S. FDA breakthrough designation https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-prostate-cancer-drug-receives-us-fda-breakthrough-designation-2021-06-16/ #prostatecancer

Dr Nickolas Papanikolaou is presenting our project ProCAncer-I at the Health IT Conference on Tuesday 15/6/21. He will talk about the creation of a platfrom containing datasets and AI models for monitoring patients with prostate cancer
@FORTH_ITE https://healthdaily.gr/2021/06/12/tin-triti-anoigei-tin-avlaia-tou-to-4o-health-it-conference/

See the first @ProCAncer_I newsletter. Get to know the ProCAncer-I project, its vision, its anonymization strategy, the legal & ethical issues that were dealt & the MRI based AI tools that will improve the management of patients with prostate cancer. https://tinyurl.com/pci-news01

🤖 #DigitalEU2030
⏰ 1 & 2 June
🖥️ Virtual event

Two days fully dedicated to new #digital technologies, opportunities & next steps to make this Europe's Digital Decade!

Join the debate 👉 http://bit.ly/DigitalEU2030

Load More...

Stay in touch!